GSK, Wavre, Belgium.
GSK, Panama City, Panama.
Hum Vaccin Immunother. 2022 Dec 31;18(1):1872341. doi: 10.1080/21645515.2021.1872341. Epub 2021 Feb 19.
The worldwide implementation of pneumococcal conjugate vaccines (PCVs) in children has reduced the overall pneumococcal disease burden. Two PCVs are widely available for infant vaccination: the pneumococcal non-typeable protein D conjugate vaccine (PHiD-CV) and the 13-valent PCV (PCV13). While these PCVs differ in serotype composition (PCV13 includes polysaccharides of serotypes 3, 6A and 19A; PHiD-CV does not), their impact on the overall pneumococcal disease burden in children is comparable. This commentary summarizes the evidence of comparability between PHiD-CV and PCV13 and explores why differences in serotype composition may not necessarily translate into a differential clinical impact. Both vaccines confer similarly high protection against disease caused by vaccine serotypes and lead to a partial replacement by non-vaccine serotypes. PHiD-CV does not protect against serotype 3 disease (not included in the vaccine) and PCV13's effect on this serotype has been inconsistent. PHiD-CV provides some cross-protection against disease caused by vaccine-related serotype 19A but neither vaccine has fully controlled 19A disease. While protection against 19A is higher for PCV13 than PHiD-CV, replacement by non-PCV13 serotypes in settings with a PCV13 program appears to compensate for this difference. This results in a similar residual overall disease burden with both vaccines.
全球范围内在儿童中使用肺炎球菌结合疫苗（PCV）已经降低了整体肺炎球菌疾病负担。有两种 PCV 广泛用于婴儿接种：肺炎球菌无荚膜蛋白 D 结合疫苗（PHiD-CV）和 13 价 PCV（PCV13）。虽然这两种 PCV 在血清型组成上有所不同（PCV13 包括血清型 3、6A 和 19A 的多糖；PHiD-CV 不包括），但它们对儿童整体肺炎球菌疾病负担的影响相当。本评论总结了 PHiD-CV 和 PCV13 之间具有可比性的证据，并探讨了为什么血清型组成的差异不一定转化为临床影响的差异。这两种疫苗对疫苗血清型引起的疾病提供了相似的高度保护，并导致非疫苗血清型的部分替代。PHiD-CV 不能预防血清型 3 疾病（不在疫苗范围内），而 PCV13 对该血清型的影响一直不一致。PHiD-CV 对疫苗相关血清型 19A 引起的疾病提供了一些交叉保护，但两种疫苗都没有完全控制 19A 疾病。虽然 PCV13 对 19A 的保护作用高于 PHiD-CV，但在有 PCV13 计划的地方，非 PCV13 血清型的替代似乎弥补了这种差异。这导致两种疫苗的残余整体疾病负担相似。
